Search

Displaying results 3171 - 3180 of 9125 in total
  1. Drug

    N4-Hydroxycytidine

    go.drugbank.com/drugs/DB15660
    Experimental

    [A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. … [A193017] N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells.

  2. Drug

    Cipepofol

    go.drugbank.com/drugs/DB16295
    ApprovedInvestigational

    Cipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated … GABA-A receptors, similar to the previously approved [propofol].

  3. Drug

    Foretinib

    go.drugbank.com/drugs/DB12307
    Investigational

    Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer.

  4. Drug

    Ethchlorvynol

    go.drugbank.com/drugs/DB00189
    ApprovedIllicitWithdrawn

    Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

  5. Drug

    Progabide

    go.drugbank.com/drugs/DB00837
    Experimental

    Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors.

  6. Drug

    Iodixanol

    go.drugbank.com/drugs/DB01249
    Approved

    Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    Veligrotug is a humanized IgG1 monoclonal antibody that binds the insulin-like growth factor-1 receptor and blocks ligand-induced receptor autophosphorylation, interrupting IGF-1R signaling. … [L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the

  8. Drug

    Plerixafor

    go.drugbank.com/drugs/DB06809
    ApprovedInvestigational

    Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. … [A7118,L45678] As an inhibitor of CXCR4, plerixafor blocks the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1α).

  9. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II. … It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Alprenolol

    go.drugbank.com/drugs/DB00866
    ApprovedWithdrawn

    One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. … Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.